Evidence map›Paper›PMID 39564635›Full record

ArticleLa Tunisie medicale2024

Saoussen Zrour, Amani Dridi, Rim Grassa, Narimane Ben Chekaya, Ismail Bejia

Abstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in La Tunisie medicale, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Saoussen ZrourRheumatology Department, CHU Fattouma Bourguiba, Faculty of Medicine of Monastir, University of Monastir, Tunisia.
Amani DridiRheumatology Department, CHU Fattouma Bourguiba, Faculty of Medicine of Monastir, University of Monastir, Tunisia.
Rim GrassaRheumatology Department, CHU Fattouma Bourguiba, Faculty of Medicine of Monastir, University of Monastir, Tunisia.
Narimane Ben ChekayaRheumatology Department, CHU Fattouma Bourguiba, Faculty of Medicine of Monastir, University of Monastir, Tunisia.
Ismail BejiaRheumatology Department, CHU Fattouma Bourguiba, Faculty of Medicine of Monastir, University of Monastir, Tunisia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo analyse the prescription of biologics (bDMARDs) in chronic inflammatory rheumatic diseases (CIRD) from Tunisian National Health Insurance (CNAM) data and to estimate their direct costs and associated factors.

methodsOne hundred and nine consecutive patients who received at least one bDMARDs during a six-month period from January to June 2022 were analysed. Clinical and therapeutic parameters as well as data related to the choice of bDMARDs were identified. Direct costs were assessed. Excess costs were considered if the monthly costs exceeded 2200 Tunisian dinars (TD) per patient.

resultsThe most common CIRD was axial spondylarthritis (AS) in 44% and rheumatoid arthritis (RA) in 37.6% of cases. Juvenile idiopathic arthritis represented 2.7% of cases. In Tunisia, prescribing of bDMARDs is concentrated in the coastal regions and follows the distribution of rheumatologists. Certolizumab pegol was the most prescribed agent in 45% of cases. No significant association was found between the choice of bDMARD and the characteristics of patients, CIRD or prescribers. The total monthly cost of bDMARDs was 225,535 ± 1269 TD. Overspending was significantly associated with initial high DAS28 in RA and young age and total hip replacement in AS.

conclusionPrescription of bDMARDs in CIRD is mainly for AS and in the coastal regions of Tunisia. The burden is considerable, partly due to the high cost of biologics. Data from this study may enable public health managers to better allocate the limited resources available for patient care and to develop medico-economic strategies to reduce health care costs.

Indexed as

Antirheumatic AgentsBiological ProductsRheumatic DiseasesAdolescentAdultAgedArthritis, JuvenileArthritis, RheumatoidCertolizumab PegolChronic DiseaseDrug CostsDrug PrescriptionsFemaleHumansMaleMiddle AgedAntirheumatic AgentsBiological ProductsCertolizumab PegolAxial spondylarthritisCostHealth InsuranceMolecular targeted therapyRheumatoid arthritisTumor Necrosis Factor Inhibitors

Identifiers

PMID39564635
PMCPMC11668151

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.